Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;7(1):84-94.
doi: 10.1016/j.sxmr.2018.09.006. Epub 2018 Nov 30.

Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications

Zachary J Solomon  1 , Jorge Rivera Mirabal  2 , Daniel J Mazur  3 , Taylor P Kohn  4 , Larry I Lipshultz  5 , Alexander W Pastuszak  6
Affiliations
Review

Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications

Zachary J Solomon et al. Sex Med Rev. 2019 Jan.

Abstract

Introduction: Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM's chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs.

Aim: To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs.

Methods: A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included.

Main outcome measure: To complete a review of peer-reviewed literature.

Results: Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results.

Conclusion: SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84-94.

Keywords: Androgens; Drug-Related Side Effects and Adverse Reactions; Hypogonadism; Selective Androgen Receptor Modulators.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Mechanism of SARM signaling.
Like androgens, SARMs enter the cytoplasm, where they displace the androgen receptor from heat shock proteins. Once bound, they translocate to the nucleus and act as transcription factors by binding androgen response elements (AREs). Depending on the tissue type and regulatory environment of the cell, different co-regulatory proteins help determine and modulate the transcriptional response. HSP = Heat shock protein. AR = Androgen Receptor. ARE = Androgen Response Element.
See this image and copyright information in PMC

References

    1. Miller CP, Shomali M, Lyttle CR, O’dea LSL, Herendeen H, Gallacher K, et al. Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Med Chem Lett 2011;2:124–9. doi:10.1021/ml1002508. - DOI - PMC - PubMed
    1. Crawford J, Prado CMM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, et al. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep 2016;18:37. doi:10.1007/s11912-016-0522-0. - DOI - PMC - PubMed
    1. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011;2:153–61. doi:10.1007/s13539-011-0034-6. - DOI - PMC - PubMed
    1. Unwalla R, Mousseau JJ, Fadeyi OO, Choi C, Parris K, Hu B, et al. Structure-Based Approach to Identify 5-[4-Hydroxyphenyl]pyrrole-2-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators. J Med Chem 2017;60:6451–7. doi:10.1021/acs.jmedchem.7b00373. - DOI - PubMed
    1. Jannini EA, Gravina GL, Mortengaler A, Morales A, Incrocci L, Hellstrom WJG. Is Testosterone a Friend or a Foe of the Prostate? J Sex Med 2011;8:946–55. doi:10.1111/j.1743-6109.2011.02233.x. - DOI - PubMed

Publication types

MeSH terms